An interventional study of Patient questionnaires and Caregiver questionnaires in Parkinson Disease, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Parkinson Disease by University Hospital, Toulouse — 7 open to participants now, 7 under way, 1 of them phase 3. Parkinson Disease · University Hospital, Toulouse.
Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, this one is the 7th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 16 with no phase, and was the 32nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →7 of the 33 studies in Parkinson Disease by University Hospital, Toulouse are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–80 · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 40–80
University Hospital, Toulouse · Sites in France
Ages 40–80
University Hospital, Toulouse · Sites in France, Germany, Spain and 1 more country
Ages 40–80
University Hospital, Toulouse · Sites in France
Ages 30–80
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 38 across the 25 interventional studies, 81 across the 8 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
3 of the studies in Parkinson Disease by University Hospital, Toulouse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189468University Hospital, ToulouseAI-based Progression and Medication Response Prediction Study in Parkinson's Disease | 2027-04-01 |
| NCT06885541University Hospital, ToulouseDetection of Internal Tremors by Oscillometry in Parkinson's Patient | 2027-05-10 |
| NCT07578272University Hospital, ToulousePrevention of Medical, Social, and Psychosocial Risks Following a Parkinson's Disease Diagnosis: A Pilot Study | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, with a prevalence expected to double by 2040. The diagnosis of PD is often a shock for patients and their families, due to a lack of preparation and adequate support. Progress has been made with the establishment of Parkinson's disease expert centers (PDECs) and better-structured care pathways, but limitations remain. The needs of patients, their caregivers, and neurologists at the time of diagnosis were studied, leading to the development of a flexible, adaptable, and multidisciplinary home-based care pathway. This pathway includes multimodal communication tools (booklet and website) and can also be used by caregivers. The aim is to evaluate this pathway at the departmental level and its ability to prevent the medical, social, and psychosocial risks that complicate the care of patients newly diagnosed with PD. Thus, offering the patient, their caregiver and their neurologist a truly flexible and local care pathway built according to their needs, from the moment the disease is announced, could allow for better acceptance of the disease, an improvement in quality of life, the adoption of beneficial practices as well as a patient-caregiver therapeutic alliance with good adherence to drug and non-drug therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients:
For caregivers (if the caregiver does not wish to participate, the patient can be included):
Exclusion Criteria:
For patients
For caregivers
- Participants who do not wish to participate
patients benefiting from a flexible and local care pathway
Other: Patient questionnaires
Other: Caregiver questionnaires
Patients will need to complete questionnaires to establish and evaluate their care pathway.
Caregivers will need to complete questionnaires in order to establish and evaluate the care plan.
Evaluate, in newly diagnosed Parkinson's patients, adherence to a new, flexible, and local care pathway after the announcement of the Parkinson's disease.
Percentage of patients who adhere to the program, i.e., who accept the partial or complete program according to their needs
Time frame: 6 months after the inclusion
Evaluation of the flexible and local care pathway based on the patient's medical and psychological parameters.
Responses to the quality of life questionnaire at baseline and 6 months post-inclusion
Time frame: 6 months after the inclusion
Evaluation of the flexible and local care pathway on the well-being of caregivers
Caregiver responses to the quality of life questionnaire at baseline and 6 months post-inclusion
Time frame: 6 months after the inclusion
Evaluation of satisfaction with the flexible and local care pathway
Responses to the satisfaction questionnaire
Time frame: 6 months after the inclusion
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →